ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CORT / forecast
CYTK (28) ARWR (58) TGTX (63) PTGX (65) ⌘ Pro Terminal →

Corcept Therapeutics Incorporated (CORT) 12-Month Stock Forecast & Price Target Cone

$80.46 -0.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $80.19

Corcept Therapeutics Incorporated (CORT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $8.77B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CORT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Corcept Therapeutics Incorporated (NASDAQ: CORT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $80.46 (-0.81% 1D, market cap $8.77B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, CORT ranks #136 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CORT compare to CYTK and ARWR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CORT carries a Roarable C (63/100 RQD), trailing P/E of 93.2x, gross margin of 96.0%, and ROIC of 4.8%. By comparison, CYTK (Cytokinetics Incorporated) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $8.76B) and ARWR (Arrowhead Pharmaceuticals Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 11.1%, cap $8.46B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CORT?
▼

Per CORT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001088856), Corcept Therapeutics Incorporated generated $761.4M in revenue (+12.8% YoY), $99.7M in net income, and $141.8M in free cash flow against $836.7M in total assets and $85.0M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $80.19 (-0.34%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 18.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510063
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk A-
Cash (13)Whales (8)SEC (18)Macro (15)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+2.2% Base Target
$133 Bull$82 Base$64 Bear
📬 FREE CORT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CORT)Realized 20D OHLCV Swing Band: ±10.3%
Deterministic 5-Pillar Attribution (63/100 Composite)
🔍 WHY CORT SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (29% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Macro Regime Fit+15/20 pts (24% of score)

FRED Regime × Technicals: 53% of 52W Range • RSI-14 at 27.6 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
71
Grade B$116.23+0% Next Q
Q2 (-2Q)
68
Grade B-$116.28-25.8% Next Q
Q3 (-1Q)
66
Grade B-$86.28-6.7% Next Q
Current
63
Grade C$80.46+0.9% Hist 90D α
Trajectory: B (71) → C (63)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CORT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, CORT faces multiple-compression risk if 93.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 93x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($109.66) or 200D SMA ($75.50) invalidates the momentum regime and cuts Target Base ($82.27) toward Bear Floor ($64.17).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CORT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CORT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 63%NO 37%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CORT Position Size: $10,000

Shares at $80.46: 124.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $64.17
$7,975
$-2,025 (-20.2%)
12M Consensus BaseTarget $82.27
$10,225
+$225 (+2.2%)
12M Bull Case BreakoutTarget $132.70
$16,493
+$6,493 (+64.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$8674%A
Goldman SachsSector Coverage LeadBUY$12569%B
JP MorganUS Large-Cap ResearchHOLD$7358%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CORT Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CORT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.93%🛡️ HOLDING TREND SUPPORT
2026-11-03O $85.95H $85.95L $80.46C $80.46VOL 1.43M
RES: $121.1SUP: $80.10SMA50: $109.7SMA200: $75.50
$132.5$107.3$82.15$57.00$31.84RES $121.1SUP $80.10$80.462026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CORT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CORT Butterfly Map → + Track CORT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +12.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CORT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CORT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CORT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CORT)

Health Care Rank #136 of 1015 ⚔️ CYTK vs CORT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CORT vs. CYTK, ARWR, TGTX, PTGX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Corcept Therapeutics Incorporated (CORT) ranks #136 by composite RQD confidence (63/100, grade C) and #121 by equity capitalization ($8.77B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with CORT at 63/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CORT ACTIVE
Corcept Therapeutics Incorporated
C 63/100 93.2x 96.0% 4.8% -0.81% $8.77B Benchmark Subject
CYTK
Cytokinetics Incorporated
E 28/100 — — -35.0% -1.52% $8.76B /cytk-vs-cort →
ARWR
Arrowhead Pharmaceuticals Inc.
D+ 58/100 — — 11.1% -0.55% $8.46B /arwr-vs-cort →
TGTX
TG Therapeutics Inc.
C 63/100 19.9x 83.7% 12.0% -2.01% $9.36B /tgtx-vs-cort →
PTGX
Protagonist Therapeutics Inc.
C 65/100 — — -16.7% -3.78% $9.37B /ptgx-vs-cort →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001088856 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Corcept Therapeutics Incorporated (CORT) reported GAAP revenue of $761.4M (+12.8% vs. FY2024 revenue of $675.0M , and +57.8% cumulative change since FY2023) , GAAP net income of $99.7M, operating cash flow of $142.0M, and free cash flow of $141.8M (-27.7% YoY). On the balance sheet, CORT closed FY2025 with $836.7M in total assets against $85.0M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $761.4M $99.7M $142.0M $141.8M $836.7M $85.0M
FY2024 (FY) 2024-12-31 $675.0M $141.2M $198.3M $196.1M $840.6M $72.4M
FY2023 (FY) 2023-12-31 $482.4M $106.1M $126.7M $105.0M $5.11B $1.20B

3. CORT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Corcept Therapeutics Incorporated (NASDAQ: CORT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $80.46 (-0.81% 1D, market cap $8.77B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, CORT ranks #136 in composite RQD confidence.

How does CORT compare to CYTK and ARWR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CORT carries a Roarable C (63/100 RQD), trailing P/E of 93.2x, gross margin of 96.0%, and ROIC of 4.8%. By comparison, CYTK (Cytokinetics Incorporated) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $8.76B) and ARWR (Arrowhead Pharmaceuticals Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 11.1%, cap $8.46B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CORT?

Per CORT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001088856), Corcept Therapeutics Incorporated generated $761.4M in revenue (+12.8% YoY), $99.7M in net income, and $141.8M in free cash flow against $836.7M in total assets and $85.0M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CORT trading relative to its 50-day, 200-day, and 52-week technical levels?

CORT last traded at $80.46 (-0.81% on volume of 1,592,518 shares), positioning the stock -26.63% below its 50-day simple moving average ($109.66) and +6.57% above its 200-day simple moving average ($75.50). Across its 52-week range of $28.66 to $126.38, CORT sits at the 53.0% percentile with a 14-day RSI of 27.6 (OVERSOLD (<32)) and an implied next-earnings move of ±10.3% ($72.17 to $88.75).

Direct Sub-Reports: CORT RQD Cockpit CORT 12M Forecast CORT Earnings & Move CORT Dividends & DRIP CORT Insiders & 13F CORT Whale Options CORT Profit Sankey CORT News & Why
ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ SEC XBRL & RQD VERIFIED

CORT — Corcept Therapeutics Incorporated: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Corcept Therapeutics Incorporated (CORT) earns a live Roarable RQD composite score of 63/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $80.46 (-0.81% 1D, market capitalization $8.77B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 4.8%, gross margin of 96.0%, operating margin of 5.9%, and free cash flow yield of 1.53%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (15/20) + Forensic Balance Sheet (18/20): Incorporates a 0.88x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 8/9, and Debt/Equity of 0.12x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Corcept Therapeutics Incorporated is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Corcept Therapeutics Incorporated (CORT) reported $761.4M in annual revenue (up from $675.0M in FY2024, +12.8% YoY) and $99.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($482.4M revenue, $106.1M net income) through FY2025, CORT scaled operating cash flow to $142.0M and free cash flow to $141.8M, backed by $836.7M in total assets against $85.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 63/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 1.53% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $28.66 – $126.38 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 93.2x trailing P/E and 95.0x EV/EBITDA against 5.9% operating margins and a 0.88x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The Genmab-related headline in the news wire is the only cross-company reference in the sources, and its second-order implications for peers cannot be quantified from the data provided.

  • Key Question #1: Can CORT sustain or expand its 5.9% operating margin and 4.8% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $761.4M and free cash flow of $141.8M, how will capital allocation balance growth reinvestment against $85.0M in total debt?
  • Key Question #3: How sensitive is CORT's 78.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.88x)?

CORT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Corcept Therapeutics Incorporated (CORT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CORT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CORT Bull vs. Bear Conversation Board — What's Your Call at $80.46?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CORT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CORT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $99.78 (+23.0%)
📌 Pinned Debate

Forensic balance sheet scores 18/20 with Altman Z of 26, Piotroski F of 8/9, and Debt/Equity of 0.12, plus a beta of 0.88.

The street is overcomplicating Corcept Therapeutics Incorporated (CORT). Forensic balance sheet scores 18/20 with Altman Z of 26, Piotroski F of 8/9, and Debt/Equity of 0.12, plus a beta of 0.88.. With an RQD score of 63/100 (C) and Forensic Balance Sheet at 18/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $87.61.

RetailWhale_TX 🐂 BULL

@RedlineAuditor Shorting a 8/20 institutional whale-flow stock at $81.12 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $67.33 (-17.0%)
Spot @ $81.12

ROIC of 4.8% and FCF yield of 1.53% against a P/E (TTM) of 93.2 leave little cash-return cushion at the current valuation.

I respect the product at Corcept Therapeutics Incorporated, but the stock at $81.12 is a different story. ROIC of 4.8% and FCF yield of 1.53% against a P/E (TTM) of 93.2 leave little cash-return cushion at the current valuation.. FCF yield is 1.53% and RQD sits at 63/100 (C) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE